Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 17/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533527 | 0.88 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL3604956 | 0.88 | BDKRB1 (0.62) | BDKRB1 | |
| SCHEMBL5517417 | 0.85 | BDKRB1 (0.41) | BDKRB1MEN1KMT2A | |
| SCHEMBL3575337 | 0.82 | BDKRB1 (0.54) | BDKRB1 | |
| SCHEMBL3575330 | 0.82 | BDKRB1 (0.54) | BDKRB1 | |
| SCHEMBL3540231 | 0.75 | BDKRB1 (0.75) | BDKRB1 | |
| SCHEMBL3538641 | 0.75 | BDKRB1 (0.75) | BDKRB1 | |
| SCHEMBL3593440 | 0.73 | BDKRB1 (0.55) | BDKRB1 | |
| SCHEMBL3541261 | 0.73 | BDKRB1 (0.77) | BDKRB1 | |
| SCHEMBL3593445 | 0.73 | BDKRB1 (0.55) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |